Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-106251
Filing Date
2026-03-13
Accepted
2026-03-13 16:31:11
Documents
117
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K gyre-20251231.htm   iXBRL 10-K 5910907
2 EX-21.1 gyre-ex21_1.htm EX-21.1 11112
3 EX-23.1 gyre-ex23_1.htm EX-23.1 4843
4 EX-31.1 gyre-ex31_1.htm EX-31.1 16993
5 EX-31.2 gyre-ex31_2.htm EX-31.2 16577
6 EX-32.1 gyre-ex32_1.htm EX-32.1 9766
7 EX-32.2 gyre-ex32_2.htm EX-32.2 9533
8 GRAPHIC img75523291_0.jpg GRAPHIC 200761
9 GRAPHIC img75523291_1.jpg GRAPHIC 155614
10 GRAPHIC img75523291_2.jpg GRAPHIC 111490
11 GRAPHIC img75523291_3.jpg GRAPHIC 2315
  Complete submission text file 0001193125-26-106251.txt   23656114

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT gyre-20251231.xsd EX-101.SCH 2690023
120 EXTRACTED XBRL INSTANCE DOCUMENT gyre-20251231_htm.xml XML 4698877
Mailing Address 12770 HIGH BLUFF DRIVE SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE SUITE 150 SAN DIEGO CA 92130 (858) 567-7770
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-51173 | Film No.: 26752940
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)